← All trials
NCT05546502
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 9, 2022
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Sep 19, 2022
- Last posted
- Dec 13, 2022
- Enrollment
- 1050
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PT Bio FarmaLead sponsor
- Universitas Gadjah MadaCollaborator
- University of IndonesiaCollaborator
- University of AndalasCollaborator
- University of AndalasOverall official - principal investigator
- University of IndonesiaOverall official - principal investigator
- University of IndonesiaOfficial
- University of AndalasOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.